Carmeliet’s research, several biocompanies have been founded and clinical trials have been launched.ĭr.

Carmeliet is on the editorial board of Cancer Cell, was a consulting editor for Science, and has more than 72 patents. Carmeliet has published more than 646 publications (94 IF>20, 243 IF>10, h-index 126) till March 2018, and is ranked by Science Match as top eight most cited authors in General Biomedicine. KU Leuven was founded in 1425 and is one of the oldest and most prestigious universities in the world.ĭr. The University of Leuven (KU Leuven) has ranked number one for many years in Europe in terms of innovation. Carmeliet is also a Professor at VIB-University of Leuven, Belgium. Carmeliet has made numerous milestone contributions to the fields.ĭr. Carmeliet is heading a world-leading research team with interests in vascular metabolism, (ocular and tumor) angiogenesis, regenerative (vascular) medicine, ocular diseases, and bioinformatic multi-omic analysis of endothelial cells in health and disease. Carmeliet is an elected member of the German Academy Sciences Leopoldina, Dutch Royal Academy of Sciences, EU Academy of Sciences, and European Molecular Biology Organization (EMBO). SYSU is the 2 nd top-ranked university in China in terms of numbers of top 1% research disciplines in the world the 2 nd in terms of campus area and the 5 th in general ranking.ĭr. SKLO and ZOC constitute the largest eye care and research center in the world. ZOC is the all-time number one eye hospital in China.

SKLO is the only one of its kind in China and is supported by the central Chinese government. Peter Carmeliet, an internationally eminent Belgian biomedical scientist, joins the State Key Laboratory of Ophthalmology (SKLO), Zhongshan Center (ZOC), Sun-Yat-Sen University (SYSU) in Guangzhou as a Guest Professor. Source: Zhongshan Ophthalmic Center of Sun Yat-sen University

Dr zoc